Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 10 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Melanoma 2 Carcinoma, Hepatocellular 2 Uterine Cervical Dysplasia 1 Triple Negative Breast Neoplasms 1 Squamous Intraepithelial Lesions 1 Prostatic Neoplasms 1 Liver Diseases 1

Interventions

Prednisone 103 enzalutamide 76 Docetaxel 72 Abiraterone Acetate 68 Leuprolide 47 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 45 abiraterone 39 apalutamide 29 Prednisolone 27 bicalutamide 26 Zoledronic Acid 24 radium Ra 223 dichloride 22 pembrolizumab 22 darolutamide 22 Goserelin 22 Triptorelin Pamoate 17 cabazitaxel 16 Androgen Antagonists 15 sipuleucel-T 13 luprolide acetate gel depot 12 Injections 12 Dexamethasone 12 olaparib 11 gallium 68 PSMA-11 10 Mitoxantrone 10 Pluvicto 9 Ipilimumab 9 Dutasteride 9 Cyclophosphamide 9 relugolix 8

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Prostatic Neoplasms × Electroporation × Clear all

NCT04972097 2026-06-02

PRESERVE

Angiodynamics, Inc.

Phase NA Completed

121 enrolled 19 charts

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡